Abstract
Gold complexes have been explored as metallodrugs with great potential applications as antitumoral agents. In particular, gold-phosphine derivatives seemed quite promising since the use of the antiarthritic auranofin drug (thiolate-Au-PEt3 complex) presented also biological activity against different cancer cells. So, different auranofin analogues have been explored within this context and for this reason, the main number of phosphine-gold complexes developed with this goal contain thiolate ligands. Other complexes have been also studied such as tetrahedral bis(phosphine)gold(I) and phosphine-gold-halides. Very recently, phosphine-gold-alkynyl complexes have also shown very interesting biological activities although few reports are published related to them. Their mechanism of action seems to be clearly different that the used by platinum drugs (DNA intercalating processes) and recent studies point to be related to the inhibition of Trx reductase. Cellular uptake and biodistribution studies are well reported in the original works but the use of luminescence techniques is relatively less explored. For this, the use of these techniques is also specifically reported in this review.
Keywords: lipophilicity, toxicity, lipophilic-cationic complexes, Gold(I), anticancer, phosphine, fluorescence, mechanism, thioredoxin, metallodrugs
Anti-Cancer Agents in Medicinal Chemistry
Title: Phosphine-Gold(I) Compounds as Anticancer Agents: General Description and Mechanisms of Action
Volume: 11 Issue: 10
Author(s): Joao Carlos Lima and Laura Rodriguez
Affiliation:
Keywords: lipophilicity, toxicity, lipophilic-cationic complexes, Gold(I), anticancer, phosphine, fluorescence, mechanism, thioredoxin, metallodrugs
Abstract: Gold complexes have been explored as metallodrugs with great potential applications as antitumoral agents. In particular, gold-phosphine derivatives seemed quite promising since the use of the antiarthritic auranofin drug (thiolate-Au-PEt3 complex) presented also biological activity against different cancer cells. So, different auranofin analogues have been explored within this context and for this reason, the main number of phosphine-gold complexes developed with this goal contain thiolate ligands. Other complexes have been also studied such as tetrahedral bis(phosphine)gold(I) and phosphine-gold-halides. Very recently, phosphine-gold-alkynyl complexes have also shown very interesting biological activities although few reports are published related to them. Their mechanism of action seems to be clearly different that the used by platinum drugs (DNA intercalating processes) and recent studies point to be related to the inhibition of Trx reductase. Cellular uptake and biodistribution studies are well reported in the original works but the use of luminescence techniques is relatively less explored. For this, the use of these techniques is also specifically reported in this review.
Export Options
About this article
Cite this article as:
Carlos Lima Joao and Rodriguez Laura, Phosphine-Gold(I) Compounds as Anticancer Agents: General Description and Mechanisms of Action, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (10) . https://dx.doi.org/10.2174/187152011797927670
DOI https://dx.doi.org/10.2174/187152011797927670 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in the Development of Anti-Infective Prophylactic and/or Therapeutic Agents Based on Toll-Like Receptor (TLRs)
Recent Patents on Anti-Infective Drug Discovery Intracellular Calcium Homeostasis and Kidney Disease
Current Medicinal Chemistry Cardiac (myo)fibroblast: Novel Strategies for its Targeting Following Myocardial Infarction
Current Pharmaceutical Design DNA Double Strand Break Repair - Related Synthetic Lethality
Current Medicinal Chemistry Recent Advances of Hepsin-Targeted Inhibitors
Current Medicinal Chemistry Can't Always Get What you Want? Try an Indirect Route you Just Might Get What you Need: A Study on Access to Genetic Data by Canadian Life Insurers
Current Pharmacogenomics and Personalized Medicine Mitocans: Mitochondrial Targeted Anti-Cancer Drugs as Improved Therapies and Related Patent Documents
Recent Patents on Anti-Cancer Drug Discovery Anti-Tumor Effects of Osthole on Different Malignant Tissues: A Review of Molecular Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Intraoperative Localisation of Impalpable Breast Lesions Utilising the ROLLIS Technique Following Peritumoral <sup>99m</sup>Tc-colloid Sentinel Node Lymphoscintigraphy
Current Radiopharmaceuticals Arsenic Trioxide Targets miR-125b in Glioma Cells
Current Pharmaceutical Design Strategic Developments & Future Perspective on Gene Therapy for Breast Cancer: Role of mTOR and Brk/ PTK6 as Molecular Targets
Current Gene Therapy Physical Activity and Cancer Prevention: Updating the Evidence. The Role of Oxidative Stress in Carcinogenesis
Current Cancer Therapy Reviews Tumor-Receptor Imaging in Breast Cancer: A Tool for Patient Selection and Response Monitoring
Current Molecular Medicine DNA Methylation, Chondrogenesis, and Cartilage Degeneration
Current Rheumatology Reviews Minimally Invasive Approach to Endometrial Cancer: Robotics and Laparoscopy
Current Women`s Health Reviews Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles
Current Pharmaceutical Design Cytokine Status of Serum in Ovarian Cancer Patients with Different Tumor Neoadjuvant Chemotherapy Response
Anti-Cancer Agents in Medicinal Chemistry Bone-Targeted Doxorubicin-Loaded Nanoparticles as a Tool for the Treatment of Skeletal Metastases
Current Cancer Drug Targets The Urokinase Receptor Interactome
Current Pharmaceutical Design Mitochondrial Serine Protease HtrA2/Omi as a Potential Therapeutic Target
Current Drug Targets